mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer

2011157 citationsJournal Articlegreen Open Access

Authors

Kathryn L. Penney · Cornell University

Jennifer A. Sinnott · Cornell University

Katja Fall · Cornell University

Yudi Pawitan · Cornell University

Yujin Hoshida · Cornell University

Peter Kraft · Cornell University

Jennifer R. Rider ·

Abstract

Our expression signature and the genes identified may improve our understanding of the de-differentiation process of prostate tumors. Additionally, the signature may have clinical applications among men with Gleason 7, by further estimating their risk of lethal prostate cancer and thereby guiding therapy decisions to improve outcomes and reduce overtreatment.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Molecular Biology Techniques and Applications

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Journal of Clinical Oncology

Volume 29, Issue 17, pp. 2391-2396

DOI: 10.1200/jco.2010.32.6421

Field-Weighted Citation Impact: 10.47